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Abstract
Purpose—To explore specific conditions and types of genetic variants that specialists in genetics
recommend should be returned as incidental findings in clinical sequencing.
Methods—Sixteen specialists in clinical genetics and/or molecular medicine selected variants in
99 common conditions to return to the ordering physician if discovered incidentally through whole
genome sequencing. For most conditions, the specialists independently considered 3 molecular
scenarios for both adults and minor children: a known pathogenic mutation, a truncating variant
presumed pathogenic (where other truncating variants were known to be pathogenic), or a
missense variant predicted in silico to be pathogenic.
Results—On average, for adults and children respectively, each specialist selected 83.5 and 79.0
conditions or genes out of 99 in the known pathogenic mutation categories, 57.0 and 53.5 out of
72 in the truncating variant categories, and 33.4 and 29.7 out of 72 in the missense variant
categories. Concordance in favor of disclosure within the adult/known pathogenic mutation
category was 100% for 21 conditions or genes and 80% or higher for 64 conditions or genes.
Conclusion—Specialists were highly concordant for the return of findings in 64 conditions or
genes if discovered incidentally during whole exome or whole genome sequencing.
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INTRODUCTION
There is an increasing consensus that whole exome sequencing (WES) and whole genome
sequencing (WGS) will continue to improve in accuracy and decline in price, and that the
use of these technologies will eventually become an integral part of clinical medicine.1–7
Several recent reports have highlighted the use of WES/WGS in the diagnosis or treatment
of patients,8–12 and there is rapid expansion of CLIA approved molecular laboratories now
providing, or soon planning to provide these services to clinicians.13–15 One of the greatest
impediments to the immediate application of sequence data to clinical medicine relates to
whether, and to what degree, molecular laboratories and clinicians should seek out, interpret
and communicate incidental or secondary (i.e. unrelated to reasons for ordering) genetic
findings.
Whatever the clinical indication for WES/WGS, there is considerable potential in each
patient to discover large numbers of variants associated with human disease.16 Currently,
there are no guidelines for return of incidental findings from clinical sequencing, although
there have been proposals for lower and higher risk categories or “bins” based upon clinical
validity and actionability.17 Yet, no one has asked whether well-meaning specialists would
agree upon incidental findings that would be appropriate to disclose. To explore
concordance or discordance that such efforts might face, 16 specialists in genetics
independently evaluated 99 common genetic conditions and individual genes and selected
those they would recommend reporting back to the patient’s physician as incidental findings
after whole genome sequencing.
MATERIALS AND METHODS
A list was generated of all diseases for which testing is clinically available as registered on
the GeneTests website.18 Genes associated with the same disease were combined. The top
88 conditions or genes based on the frequency of laboratory testing were supplemented by
adding hereditary breast and ovarian cancer, a condition that was not frequent among
laboratories due to patented genes, along with a number of common chromosomal
conditions and deletion syndromes currently diagnosed through cytogenetic analysis (Table
1).
The 16 participating specialists were clinical geneticists and/or molecular laboratory
directors, most of whom have been involved in early uses of genome-scale data, but there
was no attempt to be representative or to include all relevant sub-specialists. Each was asked
to assume that they were serving as a consultant to a laboratory that performs clinical WGS,
and to decide which variants discovered as incidental findings should be returned in a report
to the ordering physician. Specialists were asked to assume that family history was not
available, that the patient had no previously recognized clinical features consistent with the
disease variant under consideration, that the patient’s gender was known, and that it was
known whether the patient was an adult or a minor child (under 18 years), but not the exact
age. Specialists were asked to assume that the sequencing was perfectly accurate and could
detect translocations and repeat expansions with perfect accuracy, even though this degree
of accuracy is not available through current WES/WGS technologies. Details of the consent
process, patient preferences regarding results disclosure, and details about how disclosures
of results might be handled by the referring physician were not specified. An additional
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assumption was that family members of the patient being tested would not have been
sequenced or genetically tested for the variant under consideration, thus decisions were
made on the basis of the genome findings alone without contextualization by patient medical
history or family history.
Specialists provided separate responses as to whether incidental findings should be returned
to the physicians of adults and of minor children, and where applicable, in each of three
categories of variants: a known pathogenic mutation, a truncating variant presumed
pathogenic (where other truncating variants were known to be pathogenic), and a missense
variant predicted to be deleterious by in silico analysis. For recessive conditions or genes,
specialists were asked to specify whether they would return a variant even in a carrier state,
or only if the patient were found to be biallelic (for autosomal recessive) or hemizygous (for
Xlinked), or not at all. For repeat expansion disorders, specialists indicated whether they
would return a finding of a premutation or full mutation, only a full mutation, or neither. For
each possible scenario per disease (adult/child, pathogenic/truncating/missense), specialists
were also asked if they had difficulty deciding whether to report the variant. Each specialist
could decline to respond due to lack of familiarity with the condition or gene. All of the
choices described above were made through pull-down, forced-choice menus. For the
purposes of this analysis, conditions or genes were counted if the specialist recommended an
affirmative response in the dominant disorders or genes, or in any option of the recessive, X-
linked or expansion disorders or genes.
The specialists did not communicate with each other about their decisions. All 16 specialists
are listed as the co-authors of this paper. One additional co-author (SK) is a genetic
counselor who prepared the lists and assisted with data analyses and manuscript preparation,
and a second additional co-author (AM) is a contributor in ethics and legal issues who
participated in data analyses and manuscript preparation.
RESULTS
Of the 16 specialists who selected conditions, 13 were MDs with or without an additional
degree, and 3 were non-MD PhDs; 9 were primarily clinical geneticists, 3 were primarily
molecular laboratorians and 4 were active both clinically and in the molecular laboratory.
The conditions and genes proposed and the number and percentage of specialists who would
recommend return of incidental findings based upon these is shown in Table 1 (specialist
order does not correlate with order of co-authors). For each of the 99 conditions and genes,
an average of 13.5 (SD 1.9, range 8–16) specialists suggested incidental genetic findings be
returned about adults and 12.8 (SD 2.3, range 4–16) about children if there was a known
pathogenic mutation. For each of 72 conditions and genes (excluding trinucleotide repeat
expansion, chromosomal, and deletion conditions, and conditions caused by only a specific
known mutation), an average of 12.6 specialists (SD 2.3, range 8–16) and 11.9 specialists
(SD 2.2, range 7–15) suggested that incidental findings of truncating variants be returned
about adults and children, respectively. And an average of 7.4 specialists (SD 1.5, range 4–
10) and 6.6 specialists (SD 1.7, range 3–9) suggested that incidental findings of a missense
variant predicted to be pathogenic by in silico analysis be returned about adults and children,
respectively. The concordance in favor of disclosure was 100% for 21 conditions or genes in
the Adult/Known Pathogenic Mutation category, was 80% or higher for 64 conditions or
genes, and was at least 50% for all conditions or genes.
Concordance was higher for returning incidental information about conditions that had
potential for medical intervention (such as cancer predisposition syndromes) than for those
without (such as developmental or neurodegenerative disorders). Concordance was also
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higher when returning incidental findings about adults rather than about children, and for
returning known pathogenic mutations and presumed pathogenic truncating variants rather
than missense variants predicted to be pathogenic. The total number of genes or conditions
selected by each specialist varied along these axes (Table 2 and Figure 1) whereas the
discomfort that specialists felt in making the decision varied inversely along the same axes
(Table 3).
DISCUSSION
This report presents an exploratory description of concordance and discordance around
specific conditions and genes with respect to incidental findings in the context of clinical
WGS/WES. There were 21 conditions or genes in which all 16 specialists agreed that known
pathogenic mutations should be disclosed if found incidentally in adults, and 4 conditions in
which all 16 specialists agreed that known pathogenic mutations should be disclosed if
found incidentally in minor children (Table 4). There was considerable concordance among
all 99 conditions or genes for known pathogenic mutations with a majority of specialists
selecting nearly every condition or gene for return as an incidental finding.
Substantial discordance was observed across two major domains. First, some specialists
were more reluctant than others to disclose incidental findings. For example, even within the
category of adult/known pathogenic mutations, one specialist reported that he or she would
recommend disclosure of only 30.3% of the identified genes or conditions, whereas two
others thought 100% should be disclosed. Second, there was discordance in judgments about
the relative value of different criteria when making decisions about disclosures. For some,
whether the result pertained to a child or an adult seemed to be the most relevant factor
driving the decision to disclose, while for others, the established pathogenicity of the variant
was the most important factor. These criteria also influenced whether contributors found a
particular decision to be difficult. Additional research is needed to better understand the
source of this discordance; for example, whether it reflects primarily differences in clinical
or ethical judgment or, in the case of the potential pathogenicity of variants, whether
specialists were fully aware of the limited accuracy of in silico prediction tools for missense
variants.
This paper has a number of limitations. The specialists were not representative and were of
varying degrees of expertise. Each specialist responded independently and without
interaction that would characterize formal consensus building. Specialists were asked to
assume that no information was available about family history or knowledge of signs or
symptoms in relatives of the proband, which is somewhat artificial.
The degree of discordance observed suggests that whether considering incidental findings in
research subjects or incidental findings in clinical WES/WGS, it may be difficult to reach
consensus on a specific list of variants that meet a threshold for disclosure, as called for in
various consensus statements on incidental findings. However, in an actual consensus group,
experts on a subset of disorders would educate the rest of the group, and likely increase
concordance. Plans that attempt to factor in subject or patient preference (which were
excluded in this exercise) could make consensus easier or more difficult. In this exercise, the
choice was whether to provide such information in a report to the ordering physician, not to
the patient. This may have provided comfort to the specialists who were wavering because
the ordering physician would have the ability to seek preferences from the patient about how
much information to share, and the ability to contextualize the report by integrating personal
medical history, family history, symptoms and signs, or by referring the patient. The
variability in responses surrounding issues for which consensus has already been achieved
and published (such as the unreliability of in silico prediction of variant significance) also
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highlights the need for greater education, even among specialists, as well as the need for
extensively curated clinical grade databases.
In summary, there is considerable concordance and considerable discordance in choices
about return of incidental genomic information among specialists queried for this report. The
variability in responses suggests that a relatively small panel of specialists is unlikely to
embody all of the necessary expertise to achieve consensus about the vast number of genetic
variants that will be identified by WES/WGS, especially if additional variants were
considered that are less well characterized than those we selected. Modifications to a typical
consensus approach may need to be considered, such as collaboration among multiple expert
panels, with each panel being composed of specialists in a more narrow focus of expertise. It
appears that even genetic specialists are a heterogeneous group and may not be yet fully
prepared to deal with the implementation of new genetic technologies.
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Number of conditions/genes out of a total of 72 (excluding repeat expansion, chromosomal,
and deletion conditions, and conditions caused by a single known mutation) that each of 16
specialists chose for incidental return in an adult patient (1A) and in a child (1B), by
category of variant
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Table 1
Number (%) of Specialists Selecting Each Incidental Genetic Finding for Return
Condition/Gene
Known mutation Truncating variant Missense variant
Adult Child Adult Child Adult Child
Cancer
Hereditary Breast and Ovarian Cancer 16 (100.0%) 12 (75.0%) 15 (93.8%) 11 (68.8%) 9 (56.3%) 4 (25.0%)
Li-Fraumeni Syndrome 16 (100.0%) 14 (87.5%) 16 (100.0%) 13 (81.3%) 9 (56.3%) 5 (31.3%)
Lynch Syndrome 16 (100.0%) 12 (75.0%) 16 (100.0%) 11 (68.8%) 9 (56.3%) 4 (25.0%)
APC-Associated Polyposis 16 (100.0%) 15 (93.8%) 16 (100.0%) 14 (87.5%) 9 (56.3%) 7 (43.8%)
MUTYH Polyposis 16 (100.0%) 13 (81.3%) 15 (93.8%) 13 (81.3%) 9 (56.3%) 5 (31.3%)
Von Hippel-Lindau 16 (100.0%) 16 (100.0%) 16 (100.0%) 15 (93.8%) 10 (62.5%) 7 (43.8%)
MEN 1 16 (100.0%) 15 (93.8%) 16 (100.0%) 14 (87.5%) 9 (56.3%) 7 (43.8%)
MEN 2 16 (100.0%) 15 (93.8%) 15 (93.8%) 13 (81.3%) 9 (56.3%) 7 (43.8%)
PTEN Hamartoma Tumor Syndrome 16 (100.0%) 16 (100.0%) 16 (100.0%) 15 (93.8%) 8 (50.0%) 5 (31.3%)
Neurofibromatosis 1 15 (93.8%) 15 (93.8%) 15 (93.8%) 15 (93.8%) 7 (43.8%) 6 (37.5%)
Retinoblastoma 16 (100.0%) 16 (100.0%) 16 (100.0%) 15 (93.8%) 8 (50.0%) 7 (43.8%)
Metabolic/Storage
MCAD Deficiency 15 (93.8%) 15 (93.8%) 14 (87.5%) 14 (87.5%) 9 (56.3%) 8 (50.0%)
Gaucher Disease 16 (100.0%) 15 (93.8%) 15 (93.8%) 14 (87.5%) 10 (62.5%) 9 (56.3%)
Tay-Sachs Disease 15 (93.8%) 14 (87.5%) 14 (87.5%) 13 (81.3%) 9 (56.3%) 7 (43.8%)
Phenylketonuria 16 (100.0%) 15 (93.8%) 15 (93.8%) 14 (87.5%) 8 (50.0%) 8 (50.0%)
Galactosemia 16 (100.0%) 15 (93.8%) 15 (93.8%) 14 (87.5%) 9 (56.3%) 9 (56.3%)
Niemann-Pick Disease 14 (87.5%) 13 (81.3%) 13 (81.3%) 12 (75.0%) 9 (56.3%) 8 (50.0%)
VLCAD Deficiency 15 (93.8%) 14 (87.5%) 14 (87.5%) 13 (81.3%) 9 (56.3%) 9 (56.3%)
Homocystinuria 16 (100.0%) 15 (93.8%) 15 (93.8%) 14 (87.5%) 9 (56.3%) 9 (56.3%)
Tyrosinemia Type 1 16 (100.0%) 15 (93.8%) 15 (93.8%) 14 (87.5%) 9 (56.3%) 9 (56.3%)
Pompe Disease 16 (100.0%) 15 (93.8%) 15 (93.8%) 14 (87.5%) 9 (56.3%) 8 (50.0%)
Familial Dysautonomia 13 (81.3%) 13 (81.3%) 12 (75.0%) 12 (75.0%) 8 (50.0%) 8 (50.0%)
Biotinidase Deficiency 15 (93.8%) 15 (93.8%) 13 (81.3%) 13 (81.3%) 8 (50.0%) 9 (56.3%)
Isovaleric Acidemia 14 (87.5%) 14 (87.5%) 13 (81.3%) 13 (81.3%) 8 (50.0%) 9 (56.3%)
LCHAD Deficiency 13 (81.3%) 13 (81.3%) 12 (75.0%) 12 (75.0%) 8 (50.0%) 8 (50.0%)
Glutaric Acidemia Type 1 14 (87.5%) 14 (87.5%) 13 (81.3%) 13 (81.3%) 8 (50.0%) 8 (50.0%)
Citrullinemia Type 1 15 (93.8%) 15 (93.8%) 14 (87.5%) 14 (87.5%) 8 (50.0%) 8 (50.0%)
Wilson Disease 16 (100.0%) 15 (93.8%) 15 (93.8%) 14 (87.5%) 10 (62.5%) 9 (56.3%)
CPT II Deficiency 15 (93.8%) 15 (93.8%) 13 (81.3%) 13 (81.3%) 8 (50.0%) 9 (56.3%)
Mult. Acyl-CoA Dehydrogenase Def. 14 (87.5%) 14 (87.5%) 13 (81.3%) 13 (81.3%) 8 (50.0%) 8 (50.0%)
SCAD Deficiency 13 (81.3%) 13 (81.3%) 12 (75.0%) 12 (75.0%) 6 (37.5%) 6 (37.5%)
GSD Type 1a 16 (100.0%) 15 (93.8%) 15 (93.8%) 14 (87.5%) 8 (50.0%) 8 (50.0%)
Metachromatic Leukodystrophy 13 (81.3%) 13 (81.3%) 12 (75.0%) 12 (75.0%) 8 (50.0%) 7 (43.8%)
MPS Type 1 14 (87.5%) 14 (87.5%) 13 (81.3%) 13 (81.3%) 8 (50.0%) 7 (43.8%)
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Condition/Gene
Known mutation Truncating variant Missense variant
Adult Child Adult Child Adult Child
Methylmalonic Acidemia 14 (87.5%) 14 (87.5%) 13 (81.3%) 13 (81.3%) 8 (50.0%) 8 (50.0%)
Maple Syrup Urine Disease 15 (93.8%) 15 (93.8%) 14 (87.5%) 14 (87.5%) 8 (50.0%) 8 (50.0%)
Fabry Disease 16 (100.0%) 14 (87.5%) 15 (93.8%) 13 (81.3%) 10 (62.5%) 8 (50.0%)
OTC Deficiency 15 (93.8%) 15 (93.8%) 14 (87.5%) 14 (87.5%) 8 (50.0%) 8 (50.0%)
Neurological/Neuromuscular
LIS1 Lissencephaly 10 (62.5%) 10 (62.5%) 10 (62.5%) 8 (50.0%) 5 (31.3%) 5 (31.3%)
CMT Type 1A 13 (81.3%) 11 (68.8%) N/A N/A N/A N/A
CMT Type 1B 13 (81.3%) 11 (68.8%) 10 (62.5%) 9 (56.3%) 5 (31.3%) 3 (18.8%)
HNLPP 12 (75.0%) 8 (50.0%) 8 (50.0%) 7 (43.8%) 5 (31.3%) 3 (18.8%)
Early-Onset Primary Dystonia 11 (68.8%) 10 (62.5%) 8 (50.0%) 7 (43.8%) 5 (31.3%) 5 (31.3%)
Epileptic Encephalopathy Infantile 2 9 (56.3%) 9 (56.3%) 8 (50.0%) 7 (43.8%) 5 (31.3%) 5 (31.3%)
Spinal Muscular Atrophy 13 (81.3%) 13 (81.3%) 10 (62.5%) 9 (56.3%) 7 (43.8%) 5 (31.3%)
Canavan Disease 11 (68.8%) 13 (81.3%) 10 (62.5%) 10 (62.5%) 6 (37.5%) 5 (31.3%)
Dystrophinopathies 14 (87.5%) 13 (81.3%) 12 (75.0%) 11 (68.8%) 6 (37.5%) 5 (31.3%)
CMT Type X1 12 (75.0%) 11 (68.8%) 10 (62.5%) 9 (56.3%) 5 (31.3%) 3 (18.8%)
ARX-Related 11 (68.8%) 10 (62.5%) N/A N/A N/A N/A
Huntington Disease 10 (62.5%) 5 (31.3%) N/A N/A N/A N/A
Dentatorubral-Pallidoluysian Atrophy 12 (75.0%) 11 (68.8%) N/A N/A N/A N/A
Spinal and Bulbar Muscular Atrophy 13 (81.3%) 10 (62.5%) N/A N/A N/A N/A
SCA Types 1, 3, 6, 7 13 (81.3%) 11 (68.8%) N/A N/A N/A N/A
Myotonic Dystrophy Type 1 14 (87.5%) 13 (81.3%) N/A N/A N/A N/A
Friedreich Ataxia 12 (75.0%) 13 (81.3%) N/A N/A N/A N/A
Mitochondrial
Leber Hereditary Optic Neuropathy 12 (75.0%) 11 (68.8%) 10 (62.5%) 9 (56.3%) 6 (37.5%) 5 (31.3%)
MELAS 12 (75.0%) 12 (75.0%) 9 (56.3%) 9 (56.3%) 4 (25.0%) 4 (25.0%)
MERRF 12 (75.0%) 12 (75.0%) 9 (56.3%) 9 (56.3%) 4 (25.0%) 4 (25.0%)
Leigh Syndrome and NARP 12 (75.0%) 12 (75.0%) 10 (62.5%) 10 (62.5%) 5 (31.3%) 5 (31.3%)
Developmental
Noonan Syndrome 12 (75.0%) 12 (75.0%) 11 (68.8%) 11 (68.8%) 5 (31.3%) 5 (31.3%)
Beckwith-Wiedemann 14 (87.5%) 15 (93.8%) 12 (75.0%) 14 (87.5%) 6 (37.5%) 6 (37.5%)
Sotos Syndrome 12 (75.0%) 13 (81.3%) 12 (75.0%) 11 (68.8%) 6 (37.5%) 6 (37.5%)
CHARGE 12 (75.0%) 13 (81.3%) 12 (75.0%) 11 (68.8%) 6 (37.5%) 6 (37.5%)
MECP2-Related 10 (62.5%) 11 (68.8%) 10 (62.5%) 11 (68.8%) 6 (37.5%) 6 (37.5%)
FMR1-Related 13 (81.3%) 13 (81.3%) N/A N/A N/A N/A
Inherited Predisposition (non-cancer)
Factor V Leiden Thrombophilia 12 (75.0%) 9 (56.3%) N/A N/A N/A N/A
Prothrombin-Related Thrombophilia 11 (68.8%) 9 (56.3%) N/A N/A N/A N/A
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Condition/Gene
Known mutation Truncating variant Missense variant
Adult Child Adult Child Adult Child
Familial Hypercholesterolemia 16 (100.0%) 14 (87.5%) 13 (81.3%) 11 (68.8%) 7 (43.8%) 6 (37.5%)
Hereditary Hemochromatosis 14 (87.5%) 10 (62.5%) N/A N/A N/A N/A
MTHFR 9 (56.3%) 8 (50.0%) N/A N/A N/A N/A
Alpha1-Antitrypsin Deficiency 15 (93.8%) 13 (81.3%) N/A N/A N/A N/A
Gilbert Syndrome 11 (68.8%) 9 (56.3%) 10 (62.5%) 8 (50.0%) 5 (31.3%) 4 (25.0%)
Apolipoprotein E 8 (50.0%) 4 (25.0%) N/A N/A N/A N/A
Other
Achondroplasia 12 (75.0%) 12 (75.0%) N/A N/A N/A N/A
Hypochondroplasia 12 (75.0%) 13 (81.3%) N/A N/A N/A N/A
Marfan Syndrome 15 (93.8%) 15 (93.8%) 13 (81.3%) 13 (81.3%) 7 (43.8%) 7 (43.8%)
Dilated Cardiomyopathy 14 (87.5%) 13 (81.3%) 12 (75.0%) 12 (75.0%) 7 (43.8%) 7 (43.8%)
Romano-Ward (Long QT) 16 (100.0%) 16 (100.0%) 14 (87.5%) 14 (87.5%) 7 (43.8%) 7 (43.8%)
DFNA 3 Nonsyndromic Hearing Loss 12 (75.0%) 10 (62.5%) 9 (56.3%) 7 (43.8%) 7 (43.8%) 7 (43.8%)
DFNB 1 Nonsyndromic Hearing Loss 13 (81.3%) 11 (68.8%) 10 (62.5%) 8 (50.0%) 8 (50.0%) 7 (43.8%)
CFTR-Related Disorders 15 (93.8%) 14 (87.5%) 13 (81.3%) 12 (75.0%) 8 (50.0%) 7 (43.8%)
Familial Mediterranean Fever 15 (93.8%) 14 (87.5%) 11 (68.8%) 10 (62.5%) 8 (50.0%) 7 (43.8%)
Beta-Thalassemia 14 (87.5%) 13 (81.3%) 12 (75.0%) 11 (68.8%) 7 (43.8%) 6 (37.5%)
Hemoglobin SS 14 (87.5%) 13 (81.3%) N/A N/A N/A N/A
Bloom Syndrome 14 (87.5%) 15 (93.8%) 13 (81.3%) 13 (81.3%) 7 (43.8%) 6 (37.5%)
Fanconi Anemia (FANCC-Related) 15 (93.8%) 15 (93.8%) 12 (75.0%) 12 (75.0%) 7 (43.8%) 5 (31.3%)
Kallmann Syndrome 1 12 (75.0%) 12 (75.0%) 10 (62.5%) 10 (62.5%) 7 (43.8%) 7 (43.8%)
Ichthyosis, X-linked 13 (81.3%) 13 (81.3%) 11 (68.8%) 11 (68.8%) 7 (43.8%) 7 (43.8%)
Could reveal unexpected
chromosomal sex
46,XX Testicular DSD 12 (75.0%) 12 (75.0%) N/A N/A N/A N/A
Congenital Adrenal Hyperplasia 14 (87.5%) 15 (93.8%) 11 (68.8%) 12 (75.0%) 7 (43.8%) 7 (43.8%)
Androgen Insensitivity Syndrome 13 (81.3%) 13 (81.3%) 11 (68.8%) 11 (68.8%) 7 (43.8%) 8 (50.0%)
46,XY DSD and 46,XY CGD 11 (68.8%) 12 (75.0%) N/A N/A N/A N/A
Other chromosomal or deletion
syndromes
Turner Syndrome 12 (75.0%) 13 (81.3%) N/A N/A N/A N/A
Turner mosaic 12 (75.0%) 13 (81.3%) N/A N/A N/A N/A
Kleinefelter Syndrome 12 (75.0%) 13 (81.3%) N/A N/A N/A N/A
47,XYY Syndrome 12 (75.0%) 12 (75.0%) N/A N/A N/A N/A
Y Chromosome Deletion 12 (75.0%) 8 (50.0%) N/A N/A N/A N/A
22q11.2 Deletion 13 (81.3%) 14 (87.5%) N/A N/A N/A N/A
Wolf-Hirschhorn 12 (75.0%) 13 (81.3%) N/A N/A N/A N/A
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Table 2
Number (%) of Conditions Selected for Incidental Return By Each Specialist
Specialist
Known mutation (99 conditions) Truncating variant (72 conditions) Missense variant (72 conditions)
Adult Child Adult Child Adult Child
1 43 (43.4%) 43 (43.4%) 40 (55.6%) 40 (55.6%) 1 (1.4%) 1 (1.4%)
2 97 (98.0%) 90 (90.9%) 66 (91.7%) 63 (87.5%) 60 (83.3%) 57 (79.2%)
3 99 (100.0%) 99 (100.0%) 71 (98.6%) 61 (84.7%) 71 (98.6%) 61 (84.7%)
4 30 (30.3%) 46 (46.5%) 27 (37.5%) 41 (56.9%) 21 (29.2%) 30 (41.7%)
5 39 (39.3%) 39 (39.3%) 34 (47.2%) 34 (47.2%) 0 (0.0%) 0 (0.0%)
6 97 (98.0%) 97 (98.0%) 72 (100.0%) 72 (100.0%) 0 (0.0%) 0 (0.0%)
7 96 (97.0%) 92 (92.9%) 68 (94.4%) 64 (88.9%) 0 (0.0%) 0 (0.0%)
8 88 (88.9%) 80 (80.8%) 55 (76.4%) 55 (76.4%) 0 (0.0%) 0 (0.0%)
9 95 (96.0%) 94 (94.9%) 40 (55.6%) 40 (55.6%) 48 (66.7%) 39 (54.2%)
10 80 (80.8%) 76 (76.8%) 17 (23.6%) 10 (13.9%) 0 (0.0%) 0 (0.0%)
11 88 (88.9%) 88 (88.9%) 70 (97.2%) 71 (98.6%) 68 (94.4%) 68 (94.4%)
12 94 (94.9%) 93 (93.9%) 67 (93.1%) 67 (93.1%) 19 (26.4%) 26 (36.1%)
13 99 (100.0%) 38 (38.4%) 72 (100.0%) 26 (36.1%) 72 (100.0%) 26 (36.1%)
14 98 (99.0%) 98 (99.0%) 72 (100.0%) 72 (100.0%) 72 (100.0%) 72 (100.0%)
15 95 (96.0%) 94 (94.9%) 69 (95.8%) 69 (95.8%) 34 (47.2%) 37 (51.4%)
16 98 (99.0%) 97 (98.0%) 72 (100.0%) 71 (98.6%) 68 (94.4%) 58 (80.6%)
Mean 83.5 (84.3%) 79.0 (79.8%) 57.0 (79.2%) 53.5 (74.3%) 33.4 (46.4%) 29.7 (41.3%)
SD 23.6 23.2 18.8 19.2 31.3 27.3
Range 30–99 38–99 17–72 10–72 0–72 0–72
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Table 4
Genes or conditions selected by all specialists to be returned incidentally in adults. Those marked with an
asterisk were selected by all specialists to be returned incidentally in children.
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Table 5
a: Autosomal Recessive Conditions, Known Mutation— Number of Specialists Selecting Each Incidental Genetic Finding for Return if







MUTYH Polyposis 11 5 6 7
MCAD Deficiency 12 3 7 8
Gaucher Disease 13 3 8 7
Tay-Sachs Disease 13 2 8 6
Phenylketonuria 13 3 8 7
Galactosemia 13 3 8 7
Niemann-Pick Disease 13 1 8 5
VLCAD Deficiency 13 2 8 6
Homocystinuria 13 3 8 7
Tyrosinemia Type 1 13 3 8 7
Pompe Disease 13 3 8 7
Familial Dysautonomia 13 0 8 5
Biotinidase Deficiency 13 2 8 7
Isovaleric Acidemia 13 1 9 5
LCHAD Deficiency 12 1 8 5
Glutaric Acidemia Type 1 13 1 8 6
Citrullinemia Type 1 13 2 8 7
Wilson Disease 12 4 8 7
CPT II Deficiency 13 2 8 7
Mult. Acyl-CoA Dehydrogenase Def. 12 2 8 6
SCAD Deficiency 10 3 6 7
GSD Type 1a 13 3 8 7
Metachromatic Leukodystrophy 13 0 8 5
MPS Type 1 12 2 8 6
Methylmalonic Acidemia 13 1 8 6
Maple Syrup Urine Disease 13 2 8 7
Spinal Muscular Atrophy 13 0 8 5
Canavan Disease 11 0 7 6
Hereditary Hemochromatosis 10 4 7 3
MTHFR 7 2 5 3
Alpha1-Antitrypsin Deficiency 12 3 9 4
Gilbert Syndrome 9 2 6 3
CFTR-Related Disorders 13 2 8 6
DFNB 1 Nonsyndromic Hearing Loss 12 1 8 3
Familial Mediterranean Fever 11 4 8 6
Beta-Thalassemia 13 1 8 5
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a: Autosomal Recessive Conditions, Known Mutation— Number of Specialists Selecting Each Incidental Genetic Finding for Return if







Hemoglobin SS 13 1 7 6
Bloom Syndrome 12 2 8 7
Fanconi Anemia (FANCC-Related) 13 2 8 7
Congenital Adrenal Hyperplasia 12 2 8 7
b: Autosomal Recessive Conditions, Truncating Variant Presumed Pathogenic— Number of Specialists Selecting Each Incidental







MUTYH Polyposis 10 5 7 6
MCAD Deficiency 11 3 7 7
Gaucher Disease 12 3 8 6
Tay-Sachs Disease 12 2 8 5
Phenylketonuria 12 3 8 6
Galactosemia 12 3 8 6
Niemann-Pick Disease 12 1 8 4
VLCAD Deficiency 12 2 8 5
Homocystinuria 12 3 8 6
Tyrosinemia Type 1 12 3 8 6
Pompe Disease 12 3 8 6
Familial Dysautonomia 12 0 8 4
Biotinidase Deficiency 12 1 8 5
Isovaleric Acidemia 12 1 9 4
LCHAD Deficiency 10 2 8 4
Glutaric Acidemia Type 1 12 1 8 5
Citrullinemia Type 1 12 2 8 6
Wilson Disease 10 5 8 6
CPT II Deficiency 11 2 8 5
Mult. Acyl-CoA Dehydrogenase Def. 11 2 8 5
SCAD Deficiency 9 3 6 6
GSD Type 1a 12 3 8 6
Metachromatic Leukodystrophy 12 0 8 4
MPS Type 1 11 2 8 5
Methylmalonic Acidemia 12 1 8 5
Maple Syrup Urine Disease 12 2 8 6
Spinal Muscular Atrophy 10 0 5 4
Canavan Disease 10 0 4 6













Green et al. Page 16
b: Autosomal Recessive Conditions, Truncating Variant Presumed Pathogenic— Number of Specialists Selecting Each Incidental







Gilbert Syndrome 7 3 5 3
CFTR-Related Disorders 11 2 8 4
DFNB 1 Nonsyndromic Hearing Loss 9 1 7 1
Familial Mediterranean Fever 8 3 7 3
Beta-Thalassemia 11 1 8 3
Bloom Syndrome 11 2 9 4
Fanconi Anemia (FANCC-Related) 10 2 7 5
Congenital Adrenal Hyperplasia 9 2 7 5
c: Autosomal Recessive Conditions, Missense Variant Predicted Pathogenic— Number of Specialists Selecting Each Incidental Genetic







MUTYH Polyposis 5 4 3 2
MCAD Deficiency 9 0 4 4
Gaucher Disease 9 1 4 5
Tay-Sachs Disease 8 1 3 4
Phenylketonuria 8 0 4 4
Galactosemia 8 1 4 5
Niemann-Pick Disease 8 1 3 5
VLCAD Deficiency 8 1 5 4
Homocystinuria 8 1 4 5
Tyrosinemia Type 1 8 1 4 5
Pompe Disease 8 1 3 5
Familial Dysautonomia 8 0 3 5
Biotinidase Deficiency 8 0 4 5
Isovaleric Acidemia 8 0 4 5
LCHAD Deficiency 8 0 3 5
Glutaric Acidemia Type 1 8 0 3 5
Citrullinemia Type 1 8 0 3 5
Wilson Disease 8 2 5 4
CPT II Deficiency 8 0 4 5
Mult. Acyl-CoA Dehydrogenase Def. 8 0 4 4
SCAD Deficiency 6 0 3 3
GSD Type 1a 8 0 5 3
Metachromatic Leukodystrophy 8 0 3 4
MPS Type 1 8 0 3 4
Methylmalonic Acidemia 8 0 4 4
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c: Autosomal Recessive Conditions, Missense Variant Predicted Pathogenic— Number of Specialists Selecting Each Incidental Genetic







Maple Syrup Urine Disease 8 0 4 4
Spinal Muscular Atrophy 7 0 4 1
Canavan Disease 6 0 2 3
Gilbert Syndrome 4 1 3 1
CFTR-Related Disorders 6 2 5 2
DFNB 1 Nonsyndromic Hearing Loss 6 2 5 2
Familial Mediterranean Fever 6 2 5 2
Beta-Thalassemia 7 0 5 1
Bloom Syndrome 6 1 5 1
Fanconi Anemia (FANCC-Related) 5 2 4 1
Congenital Adrenal Hyperplasia 6 1 5 2
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Table 6
a: X-linked Conditions, Known Mutation— Number of Specialists Selecting Each Incidental Genetic Finding for Return if Hemizygous











Fabry Disease 13 3 9 5
OTC Deficiency 14 1 11 4
Dystrophinopathies 14 0 9 4
CMT Type X1 12 0 8 3
ARX-Related 11 0 7 3
MECP2-Related 10 0 11 0
Kallmann Syndrome 1 12 0 8 4
Ichthyosis, X-Linked 13 0 8 5
Androgen Insensitivity Syndrome 12 1 8 5
b: X-linked Conditions, Truncating Variant Presumed Pathogenic— Number of Specialists Selecting Each Incidental Genetic Finding













Fabry Disease 12 3 9 4
OTC Deficiency 13 1 11 3
Dystrophinopathies 12 0 7 4
CMT Type X1 10 0 7 2
MECP2-Related 10 0 10 1
Kallmann Syndrome 1 10 0 8 2
Ichthyosis, X-Linked 11 0 8 3
Androgen Insensitivity Syndrome 10 1 7 4
c: X-linked Conditions, Missense Variant Predicted Pathogenic— Number of Specialists Selecting Each Incidental Genetic Finding for











Fabry Disease 9 1 6 2
OTC Deficiency 8 0 6 2
Dystrophinopathies 6 0 5 0
CMT Type X1 4 1 3 0
MECP2-Related 6 0 6 0
Kallmann Syndrome 1 6 1 5 2
Ichthyosis, X-Linked 6 1 5 2
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c: X-linked Conditions, Missense Variant Predicted Pathogenic— Number of Specialists Selecting Each Incidental Genetic Finding for











Androgen Insensitivity Syndrome 6 1 5 3
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Table 7
Repeat Expansion Conditions— Number of Specialists Selecting Each Incidental Genetic Finding for Return













Huntington Disease 10 0 4 1
Spinocerebellar Ataxia Types 1, 3, 6, 7 13 0 7 4
Myotonic Dystrophy Type 1 13 1 8 5
Friedreich Ataxia 12 0 9 4
Spinal and Bulbar Muscular Atrophy 13 0 7 3
FMR1-Related Disorders 13 0 10 3
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